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Abstract
Background: The aim of this study was to characterize the spread of carbapenemase-producing Klebsiella pneumoniae
(CPKP) in a tertiary level hospital using ongoing active surveillance with rectal swab cultures. Furthermore, this study
analyzed the presence of CPKP in the clinical samples (CS) of a single patient as well as the evolution of Colistin-sensitive
strains (CoS) to Colistin-resistant strains (CoR).
Methods: This study was performed from January 1, 2012 to December 31, 2014. In 2012, a survey was conducted in
the Intensive Care Department. In autumn 2013, active monitoring was extended to the Surgery Department, and since
mid-2014, the surveillance has included the Medical Department as well. Only the first isolated strain from each patient
was included. Antimicrobial susceptibility testing was performed on CPKP isolates: Klebsiella pneumoniae carbapenemase,
oxacillinase-48, Verona integron-encoded metallo-β-lactamase and New Delhi metallo-β-lactamase were detected
using a validated in-house PCR method, and multilocus sequence typing (MLST) was used to investigate the clonal
transmission of strains.
Results: A total of 15,104 patients were included in the study, and 496 consecutive non-replicated strains of
CPKP were collected: 149 strains were collected in 2012 (39 [26.2 %] from surveillance rectal swabs [SRS]), 133
strains were collected in 2013 (70 [52.6 %] from SRS) and 214 strains were collected in 2014 (164 [76.6 %] from
SRS). We observed a significant increase in the percentage of positive SRS cases in 2014 relative to 2013 and
2012 (p = 0.0001 and p = 0.0172, respectively) and in the proportion of CPKP first isolated by SRS relative to those
identified by CS (p < 0.0001). Among all available samples, the number of CoR isolated from SRS was higher in
2013 and 2014 compared with 2012 (p = 0.0019 and p = 0.008, respectively). ST-258 and ST-512 were more
prevalent in the tested specimens, and a new single locus variant (SLV) of ST-512 (ST-745) was isolated.
Conclusions: The results of this 3-year study of 15,104 patients highlight the clinical relevance of antimicrobial
resistance as well as the drug-selection pressure of colistin therapy. The active surveillance in the three different
departments increased the level of CPKP cases isolated by SRS.
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Background
Klebsiella pneumoniae is a gram-negative that is associated
with nosocomial and community-acquired infections. Strains
of carbapenemase-producing Klebsiella pneumoniae (CPKP)
have been identified since the 1990s and have rapidly
spread in many countries [1]. The most widespread car-
bapenemase enzymes include class A carbapenemases
(KPC types), class B or metallo-β-lactamases (Verona
integron-encoded metallo-β-lactamase [VIM] and New
Delhi metallo-β-lactamase types [NDM]) and class D
oxacillinases (OXA-48-like enzymes) [2]. In addition,
the decreased susceptibility of Enterobacteriaceae to car-
bapenems may be caused by either extended-spectrum
beta-lactamases (ESBLs) or AmpC enzymes as well as de-
creased drug permeability caused by porin loss [3].
Giani et al. [4] described the first Italian report of CPKP
in 2008; since then, its detection has increased steadily. A
recent survey involving 21 Italian laboratories reported that
most carbapenem-resistant Enterobacteriaceae isolated
from clinical specimens between November 2013 and April
2014 were CPKP (93 %) [5]. The infections caused by these
organisms are difficult to treat, and relatively few treatment
options are available. The discovery and development of
newer, effective antibiotics has declined, and old agents
(e.g., colistin, particularly in combination with carbapen-
ems) have become the therapy of last resort [6, 7]. Colistin
(polymyxin E) is a bactericidal agent. Colistin sulfate and
colistimethate sodium, a prodrug that is hydrolyzed to co-
listin sulfate, are the commercially available formats. Colis-
timethate sodium is administered parenterally and exerts
its effect by interacting with lipopolysaccharide (LPS) mol-
ecules, leading to outer membrane failure and disruption
[6]. Increased use of colistin for multidrug resistant Entero-
bacteriaceae infections has led to the emergence of colistin
resistance among CPKP [5]; Monaco et al. [8] reported an
overall resistance rate of 43 %. Even more worrisome, re-
sistant strains were isolated at all included centers. More-
over, hospital outbreaks have been described in Greece
(involving two hospitals) and in the United States (involv-
ing three different institutions) [9, 10]. The resistance
mechanisms have been investigated, and the latest genomic
analyses suggest that insertional inactivation of the mgrB
gene, upregulation of the PhoP/PhoQ signaling system, ac-
tivation of the PmrA-regulated pmrHFIJKLM operon and
the presence of ArnB can lead to LPS alterations that are
linked to colistin resistance in pathogens such as K. pneu-
moniae [6, 11, 12].
The acquisition of carbapenemase-producing organisms
in the healthcare setting has serious implications for both
single patient outcomes as well as for public health. Rectal
surveillance cultures on admission allow for the timely de-
tection of infected patients and for the application of infec-
tion control measures to contain KPC-producing organisms
and to select an appropriate therapeutical choice [13, 14].
The Padua Teaching Hospital is a highly accessed ter-
tiary care hospital with 1400 recovery beds and approxi-
mately 200 admissions per day. Since 2010, an increased
incidence of CPKP clinical isolates has been reported;
for this reason, rectal swabs are used for active surveil-
lance of asymptomatic carriers.
The aim of this study was to characterize the spread of
CPKP in a tertiary care setting using ongoing active sur-
veillance, with a particular focus on the evolution of
colistin-sensitive strains (CoS) into colistin-resistant strains
(CoR) in a single patient.
Methods
Study design
This study was performed from January 1, 2012 to De-
cember 31, 2014. In 2012, a survey was conducted in the
Intensive Care Department (ICD) upon admission and
at least weekly thereafter. Subsequently, in autumn 2013,
active monitoring was extended to all patients admitted
to the Surgery Department (SD), and since mid-2014,
the surveillance has included patients in the Medicine
Department (MD) who were hospitalized in the last two
months or who arrived from long-term care facilities.
Some isolates were obtained during incidental surveys of
subjects hospitalized in the same room or in the same
ward of a positive subject. The study included both all
clinical samples (CS) from adult hospitalized patients
from whom CPKP was isolated and the rectal surveillance
cultures. Only the first CPKP strain isolated from each pa-
tient was included. The overall prevalence was evaluated
for each single year, by material (CS versus rectal swab)
and by the susceptibility or resistance to colistin.
The study was approved by the Ethical Committee for
Clinical Experimentation, Padua Province (Ethics Review
3418/AO/15). Patient consent to the study was not re-
quired as all samples were collected as part of routine
management/surveillance, and were anonymised prior to
research use. Throughout this period, infection control
measures were strengthened, especially in the wards
where a KPC was detected. In particular, isolation rooms
for colonized/infected patients were set up, or the subjects
were transferred to the infectious diseases ward. All con-
tact precautions were improved. Isolation was not feasible
in all cases because of insufficient bed capacity cases, but
the colonized or infected patients were cohorted in the
same room whenever it was possible.
Phenotypic assays
A screening test for carbapenemase-production in rectal
swabs was performed by inoculation on MacConkey II
Agar (Becton, Dickinson and Company, MD, USA),
with the automated WASP® system (Copan, Brescia,
Italy). In addition, an ertapenem disk (10 μg, BD BBL™
Sensi-Disk™) was placed on the media to identify
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suspected carbapenemase-producing colonies (screening
cut-off ≤ 25 mm) [15]. An ertapenem disk was used be-
cause of its high sensitivity in detecting carbapenemase-
producing strains.
Clinical samples were treated with routinary methods,
by using BD Chocolate Agar (GC II Agar with IsoVitaleX)
and/or BD Columbia Agar with 5 % Sheep Blood and/or
CHROMagar Orientation Medium (for urine samples).
Microbial identification was performed in all strains by
using bioMérieux Vitek® 2 and Vitek® MS. Antimicrobial
susceptibly testing was performed with a Vitek® 2 auto-
mated system. Strains that exhibited reduced susceptibility
to carbapenems (an MIC value ≥ 1 mg/L for ertapenem
and/or imipenem and/or meropenem) were also tested
using the dilution method (Thermo Scientific Sensititre™
system) for confirmation. Other phenotypic methods
employed for the detection and confirmation of carbape-
nemase were the modified Hodge test and the Rosco
Diagnostica KPC/MBL confirmation kit. Colistin suscepti-
bility, initially evaluated using the Vitek® 2 automated sys-
tem, was then confirmed with the dilution method on all
strains and with Etest® (on 52 strains in 2014) because of
possible over-estimation of resistance by automated
methods [16].
All MIC values were evaluated with EUCAST Clinical
Breakpoint tables (v 4.0) [17].
Genotypic assays
A validated in-house PCR method was used to detect KPC,
KPC type, OXA-48, VIM, and NDM carbapenemases in
cases of suspected carbapenemase-producing strains [18].
Multilocus sequence typing (MLST) was used according
to the MLST website [19] for further characterization of
the strains to investigate possible cases of intra-hospital
transmission and not for research purposes.
Statistical methods
Data were expressed as absolute numbers and percentages.
The Mann–Whitney U test was used to compare the
median values between groups. The Chi-squared test
and Fisher’s exact test were used to compare proportions
(as appropriate), and the Chi-squared test for trends was
used to evaluate the trends in proportions. Values of
p < 0.05 were considered statistically significant.
All statistical analyses were performed with MedCalc
Statistical Software version 14.12.0 (MedCalc Software
bvba, Ostend, Belgium; http://www.medcalc.org; 2014).
Results
Overall, 15,104 patients were included in the study
(2,645 subjects in 2012, 5,249 in 2013 and 7,210 in
2014), and a total of 496 consecutive non-replicated
strains of CPKP were collected, as first isolate detection
from each patient.
The identification was performed with the Hodge test
and confirmed in 496/496 strains. Rosco Diagnostica test
was performed in a subset of 93/496 KPC/MBL isolates
and we obtained the following results : in 2012, 23
strains showed synergism with meropenem and boronic
acid, and all but one were tested and confirmed by
molecular analysis; in 2013, 64 strains showed synergism
with meropenem and boronic acid (all but 12 tested
and confirmed by molecular analysis); 3 strains didn’t
showed synergism and were confirmed as OXA-48; in
2014, 3 strains showed synergism with meropenem and
boronic acid and were tested and confirmed by molecu-
lar tests. Four hundred thirty-six strains were character-
ized using molecular methods: 432 KPC strains, 3 OXA-
48 strains and 1 NDM strain were identified.
Specifically, we collected 149 CPKP strains in 2012 (39
[26.2 %] from screening rectal swabs [SRS]), 133 strains
in 2013 (70 [52.6 %] from SRS) and 214 strains in 2014
(164 [76.6 %] from SRS). The number of CPKP strains
isolated using SRS increased in 2013 relative to 2012
(p < 0.001) and in 2014 relative to 2012 and 2013; this
increase was statistically significant (p < 0.001 and p <
0.001) (Fig. 1). A higher absolute percentage (relative to
the number of patients) was reported in 2014 (2.3 %),
and this difference was significant relative to 2013
(1.3 %, p = 0.0001) and 2012 (1.5 %, p = 0.0172).
During the study period, 5,305 subjects were screened
in the ICD, 7,560 were screened in the SD, and 2,239 pa-
tients were screened in the MD. The comparative ana-
lysis of the detection of CPKP by SRS versus CS revealed
an increased rate of CPKP identified by SRS relative to
CS (Fig. 2).
In the ICD, the percentage of cases identified by SRS
was 49 % in 2012, 75 % in 2013 and 93.3 % in 2014 (the
Chi-squared test for trend, p < 0.0001); a comparable fig-
ure was described in the SD, with the highest value
(94.9 %) reported in 2014, and lower percentages in
2013 (52,4 %, p < 0.0001 respect to 2014) and in 2012
Fig. 1 Carbapenemase producing Klebsiella pneumoniae strains
isolated in 2012, 2013 and 2014. CS: clinical samples. SRS:
surveillance rectal swabs
Parisi et al. BMC Infectious Diseases  (2015) 15:244 Page 3 of 10
(23.2 %, p < 0.0001 respect to 2014 and p = 0.01 respect
to 2013). The MD department was characterized by a
sharp increase between 2012 (7.3 %) and both 2013
(31.9 %, p = 0.003) and 2014 (40.8 %, p = 0.0001).
In the ICD, this trend increased over time (from 1.5 % in
2012 to 1.8 % in 2013, and to 2.3 % in 2014). A statistically
significant difference was demonstrated in the SD between
2012 and 2013 (1.9 % versus 0.8 %, p = 0.0357) and
between 2013 and 2014 (0.8 % versus 2.2 % p < 0.0001); in
the MD the increase from 2012 (0.8 %) to 2014 (2.6 %) was
significant (p = 0.032) (Table 1).
Time to first detection of SRS was analyzed by evaluat-
ing three different figures.
In 2013, 37 % of the SRS were collected as first sample
within 7 days from admission to the hospital, 45 % after
a negative survey of one sample at least, 17 % after a
minimum stay of 7 days with no surveillance data avail-
able at least. Of note, 19 % of the SRS cases were found
positive after a negative survey of three samples at least.
About clinical samples, these rates were 33 %, 38 % and
29 % respectively.
In 2014, 27 % of the SRS were collected as first sample
within 7 days from admission, 60 % after a negative sur-
vey of one sample at least, 13 % after 7 days at least with
no survey data. About clinical samples, these rates were
52 %, 31 % and 17 % respectively. It has to be underlined
that even more SRS cases than 2013, 31 %, were found
positive after a negative survey of three samples at least.
The MLST analysis revealed the circulation of CPKP
strains previously described in other studies, including
ST-258 and ST-512. The abundance of certain prevalent
types may be partially because investigations were con-
ducted on episodes of temporal or spatial clusters. Never-
theless, some new ST variants were demonstrated: strains
510, 527, 868, 1081, 1207, 1326 and 1733. Interestingly, in
August 2011, a new single locus variant (SLV) of ST-512
(ST-745) was identified. Thereafter, the variant quickly
spread throughout the hospital. ST-745 was identified in
24 of 74 strains analyzed in 2011, when 125 patients
were demonstrated as infected or colonized by CPKP.
MLST data obtained in 2012, 2013 and 2014 are pre-
sented in Table 2.
Colistin-resistant strains
At the first detection in our survey, we collected a total
of 399 CoS strains and 97 CoR strains (Fig. 3). The per-
centage of CoR cases (both SRS and CS) relative to all
CPKP cases was 10.7 % in 2012: a statistically significant
increase respect to 2012 occurred in 2013 (25.6 %) and
in 2014 (22 %).
Fig. 2 Carbapenemase producing Klebsiella pneumoniae strains isolated from surveillance rectal swabs and from clinical samples in 2012, 2013
and 2014. IC: intensive care. CS: clinical samples. SRS: surveillance rectal swabs
Table 1 Percentage of positive SRS respect to the number of the patients involved in the surveillance in the Medical Department,
Surgical Department and Intensive Care Department in 2012, 2013 and 2014
Medical Department Surgical Department Intensive Care Department
Year Total SRS (n) Patients (n) Percentage of
positive SRS
Total SRS (n) Patients (n) Percentage of
positive SRS
Total SRS (n) Patients (n) Percentage of
positive SRS
2012 1870 486 0.8 % 924 520 1.9 % 4255 1639 1.5 %
2013 2105 630 2.4 % 5516 2767 0.8 % 5225 1852 1.8 %
2014 3207 1123 2.6 % 9441 4272 2.2 % 5501 1815 2.3 %
SRS Surveillance rectal swab
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The following overall distribution of MIC values was
observed after screening with Vitek: 372 strains exhib-
ited an MIC value ≤ 0.5 mg/L, 14 strains were MIC =
1 mg/L, 12 strains were MIC = 2 mg/L, 9 strains were
MIC = 4 mg/L, 6 strains were MIC = 8 mg/L, and 83
strains were MIC ≥ 16 mg/L. A detailed description (by
year) is provided in Fig. 4. Among the strains classified
as CoR at the first detection, 65 and 32 were identified
by SRS and CS, respectively (Fig. 5). No differences were
observed in the CS and SRS MIC values. With respect
to the clinical samples, 12 of the 32 strains were isolated
from urine cultures, 7 strains were detected in bronchial
aspirates, 6 strains from skin swabs, 2 strains from blood
cultures, 2 strains in drainage fluid, 2 strains from vagi-
nal swabs and 1 strain from a pharyngeal swab (Table 3).
Among the 65 SRS that were found to be CoR, 38 % were
collected from the patient’s first SR. The increase propor-
tion of CoR strains isolated at the first detection from SRS
in 2013 compared with 2012 was statistically significant
(p = 0.02) Moreover, we observed a significantly higher
frequency of CoR strains detected from SRS when we
compare them respect to the number of all available
CPKP cases (p = 0.0002 in 2012 versus 2013, p = 0.0034 in
2012 versus 2014).
Evolution of susceptibility to colistin
Although not from the same material (FU), a strain that
was later isolated in the same patient was also detected
in 210/399 patients with a CoS stains at first detection,
allowing us to perform a longitudinal analysis. After pre-
viously identifying a CoS strain, we identified a CoR
strain in 50/210 patients (23.8 %) (Table 4). We were
able to perform MLST for both the CoS and CoR strains
in 17 of 50 patients (Table 5). All pairs of isolates were
obtained in 2014, with the exception of the strain from
patient 14 that was detected in 2013. The same ST was
detected in both the CoS and CoR strains in 13/18
Table 2 Description of the ST- identified in carbapenemase
producing Klebsiella pneumoniae divided by Department in 2012














MD 3 1 5 - - -
SD 9 10 6 - - 1
ICD 33 5 15 2 2 -














MD 10 5 1 - -
SD 10 15 5 - 3 392 (1 pt)4
ICD 16 21 4 3 2 437 (2 pts)
12074 (1 pt)
13264 (1 pt)














MD 1 3 - - 1
SD 7 15 1 - - 395 (1 pt)
ICD 1 11 - 1 2 1199 (1 pt)
1543 (1 pt)
Total5 9 29 1 1 3 3
1 MLST available for 92/149 isolates
2 single locus variant of ST-512
3 MLST available for 100/133 isolates
4 new allelic profile
5 MLST available for 46/214 isolates
MD Medical Department, SD Surgical Department, ICD Intensive Care
Department, pt patient, pts patients
Fig. 3 Number of colistin resistant strains and colistin susceptible strains identified in 2012, 2013 and 2014. CoR: colistin resistant. CoS: colistin susceptible
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strains. In 11/13 cases, the CoS strains was also isolated
on CS. In one case, another pathogen (Enterobacter
aerogenes, susceptible only to colistin) was isolated from
a CS. None of these patients were discharged within the
time interval between the two isolates.
Four of 18 strains exhibited a different ST between the
CoS and CoR strains. Two patients were discharged dur-
ing the FU, and 2 other patients were continuously hos-
pitalized. Note that in one of these four cases, the CoR
strain (ST1733) was a single locus variant of the CoS
strain (ST554). Patient 16 reported a simultaneous isola-
tion of a ST258 CoS strains and of a ST512 CoR strain
from the same sample at the first detection.
All cases were tested to identify the KPC type; in 15
couples both isolates were KPC-3 and in one couple
both strains were KPC-2, suggesting a persisting infec-
tion with the same strain. In one case we found a KPC-2
at baseline and a KPC-3 at follow-up: this finding made
difficult a definite interpretation.
Isolation of CPKP from blood
Seventy-eight CPKP strains were isolated from the blood
of 75 patients as a first or subsequent detection: 32 in
2012 (5 CoR), 17 in 2013 (1 CoR) and 29 (6 CoR) in 2014.
The crude mortality rate among patients with CPKP iso-
lated from the blood was 35/75 (46.7 %). In cases of poor
outcomes, the median time to death was 10 days, whereas
the median time to discharge was 28 days.
Discussion
In this single-center observational analysis, we described
the changes observed over time (3 years) in the fre-
quency of CPKP detection in clinical samples and on
SRS. Furthermore, we analyzed the trend in CPKP colis-
tin susceptibility and the evolution of colistin-sensitive
to colistin-resistant strains over time.
Two strengths of this work are the updated reports
(December 2014) and the study design. The screening
program included 15,104 patients in three different clin-
ical settings at the same hospital (ICD, SD and MD), and
comparable infection control strategies were applied in
each setting.
In 2014, we observed a statistically significant increase
in the percentage of patients in whom CPKP was de-
tected by SRS (2.3 %), compared with 2012 (1.5 %) and
2013 (1.3 %). The frequency reported was lower than
that observed by Gagliotti et al. [20], who reported a
3.9 % rate in a cohort of 1,687 patients from August
to December 2011; however, the characteristics of
the screened subjects are only somewhat comparable.
Gagliotti et al. included only those subjects who were
transferred from other institutions (both hospitals and
long-term care facilities) or who were hospitalized in the
previous two months or recovered in ICDs or post-acute
wards, whereas we applied no exclusion criteria to the
surgical subjects. Moreover, we expanded the cohorts of
the involved patients over time according to their clin-
ical needs and implemented effective strategies to pre-
vent infection. The effect of this evolving pattern of
surveillance was demonstrated by the significant trend
in increased proportions of CPKP first isolated from SRS
relative to those detected in clinical samples from the
three departments.
Fig. 4 Colistin MIC values (mg/L) performed with Vitek® 2 system in
2012, 2013 and 2014. MIC: minimum inhibitory concentration
Fig. 5 Colistin resistant strains at the first detection in 2012, 2013 and 2014. CS: clinical samples. SRS: surveillance rectal samples
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The increased surveillance schedule in the MD was
matched by a significant increase in positivity from 2012
to 2014. However, the important increase in the number
cases under surveillance in the SD (520 subjects in 2012,
2,767 in 2013 and 4,272 in 2014) did not result in a de-
crease in the percentage of positive cases (1.9 % in 2012
and 2.2 % in 2014). This finding underlines the major
role of an early identification of the colonized or infected
patients and of a programmed recall of the recognized
measures to prevent transmission in all the clinical set-
tings. ICD stay is a well-known independent risk factor
for colonization with carbapenem-resistant K. pneumo-
niae [21]. Nevertheless, if we evaluate the percentage of
patients identified as carriers in 2014, comparable data
were reported in three different departments (2.3 % in
the ICD, 2.2 % in the SD and 2.6 % in the MD).
About the modality of acquisition of KPC, we cannot
exclude a previous positivity at entry in about 15 % of
SRS positive patients and in about 28 % of the patients
with a positive CS. Furthermore, we have to take into ac-
count the low susceptibility of a survey by rectal swab,
possibly due to an intermittent positivity, to a low bac-
terial load or to an incorrect sampling. Nevertheless
about at least 26 % of cases with a detection in SRS were
found positive after a previous prolonged negative sur-
vey and with a possible acquisition of KPC after the ad-
mission to the hospital.
These data justify and support the survey at entry and
the continuation of the surveillance throughout the
hospitalization, in a setting at high prevalence as the one
we described, for a better management of the colonized
subject and to limit the spread to other patients. About
the use of MLST in our cases, although the coverage of
this analysis was 61.7 % in 2012 and 75.2 % in 2013, we
were allowed to trace and confirm some clusters of in-
fection, which was useful for legal reasons, and we could
detect some new ST-variants. One of these suddenly
spread over the hospital, and molecular typing allowed
us to analyze and reform some procedures and to sensi-
tibilize health care workers to the problem. Typing also
allowed us to understand the multifaceted nature of our
KPC population. Finally, we were able to identify and
correctly interpret at least one case of co-infection with
two different ST and three cases of superinfection with a
CoR strain.
The emergence of colistin resistance may be related to
drug-selection pressure, but horizontal transmission is
a recognized cause of acquisition, and gene transfer fac-
tors (i.e., transposons and integrons) may also be in-
volved [22–24].
In 2014, the CoR detection rate (including both SRS and
CS) was 22 % among all CPKP cases. Monaco et al. [8] re-
ported a higher value (43 %) in a multicenter Italian sur-
vey, but most cases were obtained from clinical isolates.
Thirty-two of the 47 resistant strains we identified in 2014
(68.1 %) were identified by SRS, indicating a potential clin-
ical risk for the colonized subject. A later infection was de-
scribed in 9 % of patients admitted to an Israeli tertiary
care hospital, with surveillance rectal cultures that were
positive for carbapenem-resistant Klebsiella pneumoniae
after a median of 20 days [25]. Approximately half of the
15 clinical samples (46.7 %) in which a CoR strain was de-
tected were urine samples, which included both asymp-
tomatic bacteriuria and clinical urinary tract infections. In
the study by Shilo et al., patients who were diagnosed with
CRKP bacteriuria at a general hospital exhibited a high
mortality rate (29 %), perhaps because this positivity indi-
cated worse prognosis [26]. When the CRKP is colistin re-
sistant, the overall mortality rate is higher (40.6 %), and
the presence of infection is an independent negative prog-
nostic factor [27].
The detection may be a consequence of previous
hospitalization, likely because of prior antibiotic treatment.
Furthermore, possible patient-to-patient transmission is
Table 3 Description of the first detection of a colistin resistant strain in clinical samples in 2012, 2013 and 2014
Year Clinical Samples
Urine (n) Bronchial aspirates (n) Skin swab (n) Blood (n) Drainage fluid (n) Vaginal swab (n) Pharyngeal swab (n)
2012 1 4 1 1 1 0 1
2013 4 1 2 0 1 0 0
2014 7 2 3 1 0 2 0
Table 4 Longitudinal analysis of colistin susceptibility evolution in patients with a colistin susceptible isolate at the first detection in
2012, 2013 and 2014
Year CoS at first detection (n) Patients with FU available (n) CoS at FU (n) CoR at FU (n,%)
2012 133 71 59 12 (16.9 %)
2013 99 57 39 18 (31.6 %)
2014 167 82 62 20 (24.4 %)
CoS Colistin susceptible, CoR Colistin resistant, FU follow-up
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possible even outside the healthcare setting if the carrier
status is unknown due to the long-term persistence (up to
several months) of the colonization by carbapenemase-
producing enterobacteria [28, 29]. In addition, possible
horizontal transmission of colistin resistance from farm
animals to humans in Asia has been suggested by Olaitana
et al. [30], and the potential transfer of resistance genes
between species must be considered due to the extensive
use of antibiotics in veterinary medicine [31].
We identified a CoR strain in approximately one quar-
ter of the patients who exhibited a CoS strain at the first
diagnosis; a follow-up control sample is available. Colis-
tin has emerged as an effective treatment option for
multidrug resistant infections; however, drug-selection
pressure pressure probably led to the development of re-
sistance [32]. The total duration of therapy plays no role
[33], but prolonged monotherapy or suboptimal dosing
can contribute to the development of resistance [34].
Furthermore, acquired colistin resistance might persist
in the carrier and in the environment. Bogdanovich et al.
demonstrated that colistin-resistant CPKP strains persist
in cultures for 10 days in Luria-Bertani broth with no
colistin supplementation, which confirms the need for
repeated SRS checks during hospital stays [22]. In select
cases, molecular screening should be performed together
with culture testing. In our study, 4 of the 17 patients
with a CoS first isolate and follow-up CoR isolate exhib-
ited different ST; two of these patients were never dis-
charged from the hospital. We can assume that a
superinfection developed in these subjects rather than
an evolution of the strain caused by drug-selection pres-
sure. In all but one case the two strains the same KPC
variant was detected.
A limitation of this study is the lack of colistin treat-
ment data. However, the aim of this report was to de-
scribe the phenomenon of CPKP detection in clinical
Table 5 MLST analysis on pairs of CoS and CoR strains obtained from the same patient. Time to switch is intended as the
time-interval between the first CoS strain isolated from a clinical sample and the first CoR strain isolated from the same patient
Strains with Stable ST
Patient ST of the first CoS
strain isolated
Sample type Sample type of
first clinical CoS
ST of CoR strain isolated Sample type Time to switch from
CoR to CoS (days)
1 554 SRS Arterial catheter - bronchial aspirate 36
2 512 SRS skin swab - urine 26
3 307 SRS skin swab - skin swab 42
4 512 SRS skin swab - SRS 123
5 512 SRS drainage fluid - drainage fluid 28
6 512 urine urine - urine 17
7 512 SRS bronchial aspirate - SRS 74
8 1543 SRS - - SRS 50
9 512 SRS bronchial aspirate - bronchial aspirate 31
10 512 SRS bronchial aspirate - bronchial aspirate 6
11 554 SRS - - bronchial aspirate na
12 512 SRS bronchial aspirate - blood 24




Patient ST of the first CoS
strain isolated
Sample type Sample type of
first clinical CoS
ST of CoR strain isolated Sample type Time to switch from
CoR to CoS (days)
14 15 SRS urine 512 SRS 167
15 554 urine urine 512 SRS 67
16 2581 SRS skin swab 512 SRS 34
17 554 SRS arterial catheter 1733 (554 SLV) drainage fluid 54
Median:
60.5 days
1 simultaneous isolation of a ST258 CoS strains and a ST512 CoR strain from the same sample at the first detection”
CoR colistin resistant, CoS colistin susceptible, MLST Multilocus sequence typing, na not applicable, SLV single locus variant, SRS surveillance rectal swab,
ST sequence typing
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samples and SRS in a tertiary care hospital as well as to
report the trend of colistin resistance in three different
care settings and in patients over time.
Conclusions
We observed a progressive increase in the detection of
CPKP strains in the screening samples as well as a greater
number of CoR strains at the first identification, thus
demonstrating higher selection pressure for colistin resist-
ance. A colistin-resistant strain was detected in approxi-
mately one-quarter of the patients with a previous CoS
isolation, and according to the available longitudinal data,
a relevant and increasing proportion of CoR strains was
found in the surveillance rectal swabs; this finding sup-
ports the clinical relevance of surveillance rectal swabs.
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